Affimed (NASDAQ:AFMD) Receives $20.00 Consensus PT from Brokerages

Affimed (NASDAQ:AFMD) has been given a consensus rating of “Buy” by the four brokerages that are currently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $20.00.

Several research firms have recently issued reports on AFMD. Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a research report on Monday, September 9th. Laidlaw boosted their target price on Affimed from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Affimed in a report on Friday, September 6th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets raised its position in Affimed by 39.9% in the 4th quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock worth $357,000 after buying an additional 163,162 shares during the last quarter. Vestal Point Capital LP bought a new position in Affimed during the fourth quarter valued at approximately $341,000. Finally, Choreo LLC purchased a new stake in Affimed in the second quarter worth approximately $54,000. Hedge funds and other institutional investors own 30.82% of the company’s stock.

Affimed Price Performance

Shares of AFMD stock opened at $3.16 on Thursday. The company has a current ratio of 2.71, a quick ratio of 2.71 and a debt-to-equity ratio of 0.13. The business’s 50 day moving average price is $3.98 and its 200-day moving average price is $4.95. Affimed has a fifty-two week low of $2.23 and a fifty-two week high of $8.95.

Affimed (NASDAQ:AFMD) last released its quarterly earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.09). Affimed had a negative net margin of 2,922.74% and a negative return on equity of 155.30%. The company had revenue of $0.17 million during the quarter, compared to the consensus estimate of $1.67 million. On average, sell-side analysts forecast that Affimed will post -3.78 EPS for the current year.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.